Literature DB >> 15823573

Suppression of hepatitis A virus genome translation and replication by siRNAs targeting the internal ribosomal entry site.

Tatsuo Kanda1, Bo Zhang, Yuri Kusov, Osamu Yokosuka, Verena Gauss-Müller.   

Abstract

Small interfering RNAs (siRNAs) targeting the coding region of hepatitis A virus (HAV) were shown to specifically inhibit viral genome replication. Compared to the coding region, the HAV internal ribosomal entry site (IRES) in the 5' non-coding region is highly sequence-conserved and folds into stable secondary structures. Here, we report efficient and sustained RNA interference mediated by both RNase III-prepared siRNA (esiRNA) and vector-derived short hairpin RNAs (shRNAs) that are targeted to various domains of the HAV IRES. Using reporter constructs, and the DNA-based HAV replicon system, we found that shRNAs targeting the HAV IRES domains IIIc and V sustainably suppressed genome translation and replication whereas the IRES domains IIIa and IV were resistant to RNA interference. Our study suggests that some HAV IRES domains might be used as a universal and effective target for specific inhibition of HAV infection.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 15823573     DOI: 10.1016/j.bbrc.2005.03.105

Source DB:  PubMed          Journal:  Biochem Biophys Res Commun        ISSN: 0006-291X            Impact factor:   3.575


  15 in total

1.  Silencing of hepatitis A virus infection by small interfering RNAs.

Authors:  Yuri Kusov; Tatsuo Kanda; Ann Palmenberg; Jean-Yves Sgro; Verena Gauss-Müller
Journal:  J Virol       Date:  2006-06       Impact factor: 5.103

2.  Two approaches to construct mammalian expression vector of shRNA to reduce expression and replication of HBV in vitro.

Authors:  Hong-Bin Zhang; Jie Wu; Jiang Xian; Lei Pei; Jie Wang
Journal:  Mol Biol Rep       Date:  2007-06-22       Impact factor: 2.316

3.  Hepatitis A Virus Infection and Molecular Research.

Authors:  Tatsuo Kanda; Reina Sasaki-Tanaka; Shingo Nakamoto
Journal:  Int J Mol Sci       Date:  2022-06-29       Impact factor: 6.208

4.  Small interfering RNA targeted to hepatitis C virus 5' nontranslated region exerts potent antiviral effect.

Authors:  Tatsuo Kanda; Robert Steele; Ranjit Ray; Ratna B Ray
Journal:  J Virol       Date:  2006-11-01       Impact factor: 5.103

5.  Inhibitory effects on HAV IRES-mediated translation and replication by a combination of amantadine and interferon-alpha.

Authors:  Lingli Yang; Tomoko Kiyohara; Tatsuo Kanda; Fumio Imazeki; Keiichi Fujiwara; Verena Gauss-Müller; Koji Ishii; Takaji Wakita; Osamu Yokosuka
Journal:  Virol J       Date:  2010-09-03       Impact factor: 4.099

6.  Human immunodeficiency virus type 1 escape is restricted when conserved genome sequences are targeted by RNA interference.

Authors:  Karin Jasmijn von Eije; Olivier ter Brake; Ben Berkhout
Journal:  J Virol       Date:  2007-12-12       Impact factor: 5.103

7.  Hepatitis A virus-encoded miRNAs attenuate the accumulation of viral genomic RNAs in infected cells.

Authors:  Jiandong Shi; Jing Sun; Meini Wu; Ningzhu Hu; Yunzhang Hu
Journal:  Virus Genes       Date:  2016-03-02       Impact factor: 2.332

8.  Analysis of 5' nontranslated region of hepatitis A viral RNA genotype I from South Korea: comparison with disease severities.

Authors:  Tatsuo Kanda; Sook-Hyang Jeong; Fumio Imazeki; Keiichi Fujiwara; Osamu Yokosuka
Journal:  PLoS One       Date:  2010-12-28       Impact factor: 3.240

Review 9.  Direct-acting Antivirals and Host-targeting Agents against the Hepatitis A Virus.

Authors:  Tatsuo Kanda; Shingo Nakamoto; Shuang Wu; Masato Nakamura; Xia Jiang; Yuki Haga; Reina Sasaki; Osamu Yokosuka
Journal:  J Clin Transl Hepatol       Date:  2015-09-15

10.  Suppression of La antigen exerts potential antiviral effects against hepatitis A virus.

Authors:  Xia Jiang; Tatsuo Kanda; Shuang Wu; Shingo Nakamoto; Kengo Saito; Hiroshi Shirasawa; Tomoko Kiyohara; Koji Ishii; Takaji Wakita; Hiroaki Okamoto; Osamu Yokosuka
Journal:  PLoS One       Date:  2014-07-07       Impact factor: 3.240

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.